“Substantially all” Australian generics business to be acquired for undisclosed price.
Amneal Pharmaceuticals is set to acquire “substantially all” of Actavis Australia’s generics business in the country, with a letter of intent signed.
The companies said they would work quickly to complete the acquisition for an undisclosed amount to prevent disruption of supply, with Actavis continuing to supply generics on the Pharmaceutical Benefits Scheme and for its hospital tenders until complete.
Actavis would continue to distribute its non-generic medicines, the company said, while Allergan would continue to supply “Botox, eye-care products and all other heritage Allergan products”.
The deal was subject to completion of confirmatory due diligence and definitive agreements, the companies said.
For more, see tomorrow’s Pharmacy Daily.
